MedPath

Efficacy and Safety of AJU-S56 in Dry Eye Syndrome Patients

Phase 2
Completed
Conditions
Dry Eye Syndromes
Interventions
Drug: (AJU-S56 5% and placebo)
Drug: Placebo(Vehicle)
Registration Number
NCT06337981
Lead Sponsor
AJU Pharm Co., Ltd.
Brief Summary

This study is planned to Evaluate the Efficacy and Safety of test drug (AJU-S56) compared to control drug(vehicle) in Patients with Dry Eye Disease.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
99
Inclusion Criteria
  • Male and Female who over 19 years old
  • Moderate to Severe Dry Eye Disease Patients
  • Must meet all criteria listed below at least in one eye or both eyes. TCSS (National eye institute (NEI) scale)≥ 4 Schirmer test(without anesthesia) ≤ 10mm in 5 mins Tear break-up time ≤ 6 secs
  • Written informed consent to participate in the trial
Exclusion Criteria
  • Those who have clinically significant eye disease not related to dry eye syndrome
  • Those who have medical history with intraocular surgery 12months before screening visit
  • Use of corticosteroid, beta blocker and anticholinergic agent within 4 weeks
  • Participation in other studies within 4weeks of screening visit

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Test group 1(AJU-S56 5% and placebo)(AJU-S56 5%) and placebo(Vehicle), 1drop/1times, 3times in a day
Test group 2AJU-S56 5%(AJU-S56 5%), 1drop/1times, 6times in a day
Comparator groupPlacebo(Vehicle)Placebo(Vehicle), 1drop/1times, 6times in a day
Primary Outcome Measures
NameTimeMethod
Total corneal staining score (TCSS)WEEK 4(Visit 4) (*Baseline, Visit 2 is performed in Day 0, Week 0)

Total corneal staining score (TCSS) ≥4 at baseline (Total Max score : 15, bigger socre means worse outcome)

Secondary Outcome Measures
NameTimeMethod
LGCSSWEEK 2(Visit 3), 4(Visit 4), 8(Visit 5), 12(Visit 12) (*Baseline, Visit 2 is performed in Day 0, Week 0)

Lissamine Green Conjunctival Staining Score(Total score : 0\~18)

TFBUTWEEK 2(Visit 3), 4(Visit 4), 8(Visit 5), 12(Visit 12) (*Baseline, Visit 2 is performed in Day 0, Week 0)

Tear Film Break Up Time

Trial Locations

Locations (1)

AJU Pharm Co., Ltd.

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath